Chronic insomnia affects approximately 10-16% of the population, causing difficulty falling asleep, staying asleep, or achieving restorative sleep that significantly impacts daytime function, mood, and overall wellbeing. When traditional treatments like cognitive behavioral therapy and medications haven’t provided adequate relief, transcranial magnetic stimulation (TMS) offers an evidence-based alternative. At Complete Mind Care of PA, our experienced team of over 20 board-certified providers offers advanced neuromodulation treatments for sleep disorders as part of comprehensive brain wellness care.
Our leadership team brings extensive experience from building a successful 35-location TMS practice, giving us deep expertise in neuromodulation treatments. We serve more than 4,500 active patients across our Horsham and Villanova locations with extended hours (7 AM – 8 PM weekdays) to accommodate your schedule.
We understand that chronic insomnia affects every aspect of life—work performance, relationships, mental health, and physical wellbeing. Remission is our mission, and we’re committed to exploring evidence-based approaches that may help you achieve the restorative sleep you need to thrive.
Chronic insomnia is characterized by persistent difficulty initiating sleep, maintaining sleep, or experiencing non-restorative sleep despite adequate opportunity for sleep. According to diagnostic criteria, insomnia disorder involves sleep difficulties occurring at least three nights per week for at least three months, accompanied by significant daytime dysfunction.
Nighttime Symptoms:
Daytime Consequences:
Primary Insomnia: Sleep difficulty not attributable to another medical, psychiatric, or sleep disorder. Often involves learned sleep-preventing associations, heightened physiological and cognitive arousal, and perpetuating behaviors that maintain the insomnia.
Comorbid Insomnia: Sleep difficulty occurring alongside other conditions such as depression, anxiety disorders, chronic pain, medical illnesses, or other sleep disorders. The insomnia and comorbid condition often interact bidirectionally, each worsening the other.
Onset Insomnia: Primarily difficulty initiating sleep at bedtime.
Maintenance Insomnia: Primarily difficulty staying asleep, with frequent or prolonged awakenings.
Early Morning Awakening: Waking significantly earlier than desired with inability to return to sleep.
Contemporary research understands chronic insomnia as involving hyperarousal—a persistent state of increased physiological, cognitive, and cortical activation during both daytime and nighttime hours. Neuroimaging and neurophysiological studies show individuals with chronic insomnia have:
Altered cortical excitability: Studies using TMS as an assessment tool reveal that insomnia patients show disturbed cortical excitability patterns that clearly differ from healthy sleepers and from other sleep disorders. Reduced intracortical inhibition and altered cortical-evoked responses suggest imbalances in excitatory and inhibitory brain circuits.
Overactive arousal systems: Heightened activity in brain regions responsible for wakefulness and alertness, including increased beta and gamma wave activity during sleep onset and light sleep stages when the brain should be transitioning to sleep.
Disrupted sleep-wake regulation: Dysfunction in brain networks that normally facilitate the transition between wakefulness and sleep, involving multiple neurotransmitter systems including GABA (inhibitory), glutamate (excitatory), and others.
Altered functional connectivity: Abnormal communication patterns between brain regions responsible for sleep-wake regulation, attention, emotion, and arousal control.
Increased neuroplasticity in motor cortex: Research shows particular brain regions, including the motor cortex, demonstrate more neuroplasticity in patients with chronic insomnia compared to good sleepers, suggesting maladaptive brain changes that perpetuate poor sleep.
Standard insomnia treatment includes cognitive behavioral therapy for insomnia (CBT-I)—considered the gold standard first-line treatment—which addresses thoughts, behaviors, and habits that interfere with sleep. Pharmacological treatments include prescription sleep medications (benzodiazepines, non-benzodiazepine hypnotics, melatonin receptor agonists, orexin receptor antagonists) and over-the-counter options. Sleep hygiene education, relaxation training, stimulus control, sleep restriction, and mindfulness techniques are also commonly recommended.
However, CBT-I faces barriers including limited access to trained providers, time commitment, and patient adherence challenges. Medications carry risks of side effects, tolerance, dependence, next-day sedation, and limited long-term effectiveness. Many individuals need additional or alternative treatment options.
Important Note: TMS is not FDA-approved for treating insomnia or sleep disorders. At Complete Mind Care of PA, we offer TMS for sleep difficulties as an advanced treatment option based on substantial research evidence. This treatment is provided on a cash-pay basis and should be viewed as complementary to standard sleep medicine approaches, not a replacement for comprehensive sleep care.
Research has primarily explored low-frequency repetitive TMS (rTMS) targeting specific brain regions involved in arousal and sleep regulation:
Right Dorsolateral Prefrontal Cortex (DLPFC): The most extensively studied target for primary insomnia. Low-frequency stimulation (typically 1 Hz) helps reduce cortical hyperexcitability and normalize overactive arousal systems. The right DLPFC plays a key role in executive function, attention, and arousal regulation.
Posterior Parietal Cortex (PPC): An alternative target showing promise for reducing arousal and improving sleep quality through modulation of attention networks and sensory processing.
Studies suggest low-frequency rTMS works by normalizing the hyperarousal state characteristic of insomnia, restoring balance in excitatory and inhibitory brain circuits, enhancing sleep-promoting neural activity, and improving natural sleep-wake regulation.
Chronic insomnia involves dysfunction in the brain’s sleep-wake regulation systems, characterized by a persistent state of hyperarousal. The hyperarousal model of insomnia suggests multiple levels of increased activation:
Physiological hyperarousal: Elevated heart rate, body temperature, cortisol levels, and metabolic rate during sleep attempts
Cognitive hyperarousal: Racing thoughts, rumination, worry, and inability to “turn off” mental activity when trying to sleep
Cortical hyperarousal: Excessive high-frequency brain activity (beta and gamma waves) during periods when the brain should show sleep-related slow-wave patterns
Neuroimaging and neurophysiological research demonstrates that individuals with chronic insomnia show:
TMS delivers magnetic pulses through a coil placed on the scalp, creating electrical currents that modulate neural activity. Low-frequency stimulation protocols work through multiple mechanisms:
Reduction of cortical hyperexcitability: Low-frequency rTMS (1 Hz) has inhibitory effects that reduce excessive cortical activation. Studies show rTMS normalizes the elevated cortical excitability characteristic of insomnia, helping quiet overactive arousal systems and facilitating the transition to sleep.
Restoration of inhibitory-excitatory balance: TMS modulates the balance between inhibitory (GABA) and excitatory (glutamate) neurotransmission in cortical circuits. By enhancing inhibitory activity, rTMS helps restore the neurochemical environment needed for sleep initiation and maintenance.
Normalization of sleep architecture: Research demonstrates rTMS increases slow-wave sleep (deep sleep, Stage 3 NREM) and REM sleep duration—the two most restorative sleep stages critical for physical restoration, memory consolidation, emotional regulation, and overall wellbeing.
Modulation of sleep-wake networks: By targeting the right DLPFC or posterior parietal cortex, TMS influences interconnected networks involved in arousal regulation, attention control, and sleep-wake transitions. This helps restore more normal communication between brain regions that coordinate sleep and wakefulness.
Neuroplastic changes: Repeated rTMS sessions induce lasting changes in neural circuits involved in sleep regulation. Over time, these neuroplastic adaptations may help establish more sustainable improvements in sleep patterns.
Reduction of arousal-related neural activity: Functional imaging studies show TMS reduces activity in brain regions associated with heightened arousal, helping decrease the physiological and cognitive activation that interferes with sleep.
Improvement of circadian regulation: Some evidence suggests TMS may influence circadian rhythm regulation and the natural timing of sleep-wake cycles, though mechanisms remain under investigation.
The evidence base for TMS in sleep disorders has grown substantially in recent years:
A landmark systematic review and meta-analysis published in Sleep Medicine in 2021 examined 36 trials from 28 studies involving 2,357 adults with insomnia (mean age 48.8 years, approximately balanced male and female). The analysis evaluated rTMS efficacy and safety for insomnia either as monotherapy or as a complementary strategy. Results showed rTMS was associated with significantly improved Pittsburgh Sleep Quality Index (PSQI) total scores compared to sham stimulation, with large effect sizes. Compared to sham rTMS, active rTMS improved PSQI total score (effect size -2.31) and all seven subscale components including sleep latency, sleep duration, sleep efficiency, sleep disturbance, daytime dysfunction, and medication use. When compared to other treatments, rTMS as monotherapy or adjunctive therapy also showed significant improvements. Polysomnography outcomes indicated rTMS improves sleep quality through increasing slow-wave sleep and REM sleep. The treatment was safe and well-tolerated, with headache being the most common side effect.
A 2019 systematic review and meta-analysis specifically examining rTMS for primary insomnia found pooled effect sizes showing significant improvement in insomnia symptoms. The PSQI effect size was -0.98 for 10 days of treatment, -1.16 for 20 days, and -2.14 for 30 days, demonstrating dose-response relationship with treatment duration.
A comparative study of 120 patients with primary chronic insomnia divided participants into three groups receiving either low-frequency rTMS, benzodiazepine medication, or cognitive behavioral therapy for two weeks. TMS increased total average sleep time by 25% and was superior to both medication and psychotherapy at improving REM sleep. Unlike medication and CBT, TMS-treated patients showed the lowest relapse rates. Stress levels were restored toward normal and no side effects were reported.
Research examining objective sleep measurements via polysomnography shows rTMS targeting the right DLPFC produces significant improvements in sleep architecture including increased Stage 3 (deep sleep) and REM sleep duration, reduced sleep onset latency, decreased wake after sleep onset, and improved sleep efficiency. These objective improvements correlate with subjective reports of better sleep quality.
A meta-analysis comparing different treatment modalities found that rTMS significantly reduced cortical arousal levels and provided better long-term treatment effects compared to medications and psychotherapy alone, with sustained improvements maintained at 3-month follow-up.
Studies in patients with depression and comorbid insomnia show TMS improves both mood and sleep quality, with sleep improvements occurring independently of depression improvement in many cases. This suggests direct effects on sleep regulatory circuits rather than solely indirect effects through mood improvement.
Treatment begins with thorough assessment by our board-certified psychiatrists or psychiatric nurse practitioners. We’ll review:
We’ll conduct standardized sleep assessments including the Pittsburgh Sleep Quality Index (PSQI) and Insomnia Severity Index (ISI). We’ll determine the most appropriate TMS protocol for your specific presentation and rule out contraindications.
TMS protocols for sleep disorders typically involve:
Target: Right dorsolateral prefrontal cortex (DLPFC) or posterior parietal cortex (PPC)
Frequency: Low-frequency stimulation at 1 Hz (inhibitory protocol to reduce cortical hyperexcitability)
Intensity: 80-120% of your resting motor threshold
Pulses: 1000-1800 pulses per session
Induction phase: Daily sessions Monday through Friday for 2-4 weeks (10-20 sessions)
Maintenance phase: Weekly or bi-weekly sessions for 4-8 weeks in extended protocols
Session duration: 15-30 minutes depending on the protocol
Our team will design a personalized protocol based on current research evidence, your specific sleep difficulties, and treatment goals.
You’ll sit comfortably in a recliner while the TMS coil is positioned over your scalp targeting the right prefrontal or parietal region. The treatment produces clicking sounds and creates a tapping sensation on your scalp. Most patients tolerate this well and many find the experience relaxing. You’ll remain awake and alert throughout treatment—many patients use this time to practice relaxation or simply rest quietly. You can drive yourself to and from appointments and resume normal activities immediately.
Unlike sleep medications, TMS doesn’t cause next-day sedation, grogginess, or cognitive impairment. Sessions are typically scheduled in late afternoon or early evening when convenient for most patients’ work schedules.
We use standardized assessments to track changes in:
Regular check-ins help us understand how treatment is affecting your sleep patterns and adjust our approach as needed.
Sleep improvements with rTMS typically emerge gradually. Some patients notice subtle changes in sleep quality or reduced sleep onset latency within the first 1-2 weeks. More substantial improvements in total sleep time, sleep efficiency, and sleep architecture generally become apparent after 2-4 weeks of treatment (10-20 sessions).
Based on clinical trial data, sleep quality continues to improve with longer treatment duration, with optimal benefits often reached around 4-6 weeks. Studies show effects are maintained at follow-up assessments one month and three months after treatment completion. Unlike medications that stop working immediately when discontinued, TMS appears to produce more durable changes in sleep regulation.
TMS for sleep disorders may be appropriate if you:
FDA status: TMS for insomnia and sleep disorders is investigational and not FDA-approved. Evidence is substantial and growing, particularly for low-frequency right DLPFC stimulation in primary chronic insomnia, but ongoing research is needed to optimize protocols and understand who benefits most.
Not a replacement for comprehensive sleep care: TMS should complement, not replace, standard sleep medicine approaches including sleep hygiene, CBT-I techniques, treatment of underlying conditions, and appropriate use of medications when needed. Continue all treatments recommended by your sleep specialist or physician.
Individual response variability: Research shows meaningful sleep improvement in a majority of patients treated with rTMS, with some experiencing dramatic benefits. However, response varies between individuals. Factors like duration of insomnia, comorbid depression or anxiety, medication use, and adherence to sleep hygiene principles may influence outcomes.
Type of sleep disorder matters: The strongest evidence supports TMS for primary chronic insomnia and insomnia comorbid with depression or anxiety. Evidence for other sleep disorders like restless legs syndrome, narcolepsy, or sleep apnea is more limited or investigational. TMS cannot replace CPAP therapy for sleep apnea.
Time and financial commitment: A full protocol involves 10-20+ sessions over 2-6 weeks initially, with possible maintenance sessions. This requires scheduling flexibility and financial resources. Our extended hours help accommodate work schedules.
Behavioral sleep strategies remain important: TMS works best when combined with good sleep practices including consistent sleep-wake schedule, appropriate sleep environment (dark, quiet, cool), limiting screens before bed, managing stress, and other sleep hygiene principles.
We recognize that chronic insomnia can feel isolating and frustrating, especially when well-meaning advice like “just relax” doesn’t help. Our team provides understanding, non-judgmental care that respects the real neurobiological basis of your sleep difficulties.
We understand that chronic sleep deprivation affects every aspect of life—work performance, relationships, mental health, physical health, and overall quality of life. Our goal is not just improving sleep numbers, but helping you reclaim the energy, focus, and wellbeing that restorative sleep provides.
Our comfortable, private treatment rooms offer a calm environment conducive to relaxation. We work collaboratively with your existing healthcare providers—sleep specialists, primary care physicians, psychiatrists, and psychologists—to ensure comprehensive care. All TMS sessions are supervised by our trained clinical staff with immediate access to our board-certified psychiatric providers who have extensive experience in neuromodulation and sleep medicine.
Because TMS for sleep disorders is not FDA-approved for this indication, this treatment is not covered by insurance and is provided on a cash-pay basis. We provide transparent pricing during your consultation so you can make informed decisions about whether this investment aligns with your healthcare priorities.
Given the significant financial commitment and investigational nature of this treatment, we encourage careful consideration and discussion with your medical team before proceeding. Our team can provide documentation for any reimbursement requests you wish to pursue with your insurance carrier, though coverage is unlikely.
Unlike medications, TMS directly modulates the brain circuits involved in sleep-wake regulation rather than chemically inducing sedation. TMS doesn’t cause next-day grogginess, doesn’t risk tolerance or dependence, has minimal side effects, and appears to produce more lasting changes. However, TMS requires multiple sessions and time commitment, whereas medication works immediately. Many patients use TMS to reduce or eliminate sleep medication dependence.
The strongest evidence supports TMS for chronic primary insomnia and insomnia comorbid with mood disorders. Some preliminary research shows potential benefits for restless legs syndrome. TMS cannot replace CPAP therapy for obstructive sleep apnea. If you have multiple sleep issues, comprehensive evaluation by a sleep specialist is important to identify all contributing factors.
Yes. Research includes patients with chronic insomnia of varying durations, including long-standing cases. While acute insomnia may resolve more quickly, chronic insomnia also responds to TMS treatment. The key is that TMS works by addressing the underlying neurobiological changes that maintain chronic insomnia, regardless of how long you’ve had sleep difficulties.
Disclaimer: TMS for insomnia and sleep disorders is an investigational treatment approach and is not FDA-approved for these indications. Individual results vary significantly. This treatment should be viewed as complementary to, not replacement for, standard sleep medicine care including cognitive behavioral therapy for insomnia and appropriate medical management. This information is for educational purposes and does not constitute medical advice. Consult with qualified healthcare providers specializing in sleep medicine to determine if TMS is appropriate for your situation.
Conditions Treated
721 Dresher Rd # 1100, Horsham, PA 19044
721 Dresher Rd # 1100, Horsham, PA 19044
Complete Mind Care was founded on the premise of providing full mental health support delivered by a team of expert professionals, in the comfort of a world-class facility local to you—so you can build a foundation for lasting recovery close to home. Plus 40+ additional insurance carriers accepted.
Don’t see your insurance listed? Call our office at 215-607-7250 or 215-918-7939 to verify coverage.
